The EuroBiotech Journal (Sep 2018)

Genetic testing for Ebstein anomaly

  • Rakhmanov Yeltay,
  • Maltese Paolo Enrico,
  • Bruson Alice,
  • Beccari Tommaso,
  • Dundar Munis,
  • Bertelli Matteo

DOI
https://doi.org/10.2478/ebtj-2018-0038
Journal volume & issue
Vol. 2, no. s1
pp. 55 – 57

Abstract

Read online

Ebstein anomaly (EA) is a rare congenital tricuspid valve malformation, characterized by downward displacement of the septal leaflet and an atrialized right ventricle. About 80% of cases of EA are non-syndromic; in the other 20%, the anomaly is associated with a chromosomal or Mendelian syndrome. The prevalence of EA is estimated at about 1 per 20,000 live births, and accounts for less than 1% of all congenital heart defects. EA has autosomal dominant inheritance. Likely causative genes are: NKX2-5, MYH7 and TPM1. This Utility Gene Test was developed on the basis of an analysis of the literature and existing diagnostic protocols. It is useful for confirming diagnosis, as well as for differential diagnosis, potential risk assessment and access to clinical trials.

Keywords